Genmab — Januar 2015
-
syntes mere og mere det ligner en større markedskorrektion snart og med de stigninger genmab har haft kunne jeg godt forestille mig den lige skal backteste 330-340 igen før videre optur
-
Kender I det med at side med fornemmelsen, at "nogen ved noget" med de stigninger, der har været. Det bliver bare ved og ved. Nu rammer vi snart finanhusenes kursmål - spændende, hvad der så sker, og ikke mindst hvad der skal drive kursen sub. evt. holde den nogenlunde ved en korrektion....
-
DAX er i minus 2% så at vi stadig er i + skal vi nok bare være glade for
-
GSK will be granted exclusive rights in relation to ofatumumab for use in multiple
sclerosis, rheumatoid arthritis, pemphigus, neuromyelitis optica and in the field of autoimmune diseases
(subject to a right of first negotiation in favour of Novartis in the event that GSK wishes to divest the licence
or enter into certain co-development/commercialisation activities in relation to the relevant compound,
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind